cardiovascular risk

Switching from Byetta to Wegovy or Zepbound: Why Many Patients Are Transitioning to Newer GLP-1 Therapies

by

Patients using older GLP-1 medications like Byetta are increasingly transitioning to newer therapies such as Wegovy and Zepbound. Here’s how the switching process works, why dose escalation matters, and what clinicians consider when choosing between semaglutide and tirzepatide.

Why Zepbound Users Lose More Weight Than Wegovy Users

by

New clinical trial data show that Zepbound users lost significantly more weight than Wegovy users over 72 weeks. Here’s how tirzepatide and semaglutide compare in effectiveness, side effects, cardiovascular benefits, and obesity treatment outcomes.